Barbara J. Dalton

Barbara Dalton, Ph.D., is Senior Managing Partner and Vice President of Worldwide Business Development at Pfizer Ventures. Barbara has led Pfizer Ventures since joining Pfizer in 2007. The venture team has invested in over 100 companies and approximately 20 funds pursuing products, technologies and services, relevant to all aspects of Pfizer’s business, since inception in 2004. The team has been successful in fulfilling their goal of providing financial and strategic returns to Pfizer. Barbara has overall responsibility for Pfizer Ventures and directly manages investments in all funds and the portfolio companies: AMRA, Artios, Cydan, Imara, Ixchelsis, Levicept, Ravenna, Second Genome and Simcha. She also chairs the Healthcare Advisory Board of the Partnership Fund for NYC.

Barbara’s pharmaceutical career started in the Immunology Division of Smith Kline & French Research Laboratories. She moved to venture investing in 1993 when she joined their venture capital group, S.R. One, Limited. In 2000 Barbara became a General Partner in the private venture fund, EuclidSR Partners, that was supported by GSK (then SB) as a sister fund to S.R. One, Limited.

Barbara received her undergraduate degree from Penn State and her Ph.D. from the Medical College of Pennsylvania.